HIV AND NOVEL STRATEGIES FOR INDUCTION OF BROAD NEUTRALIZING ANTIBODIES FOLLOWING VACCINATION: Edited by Ralf WagnerProgress in HIV-1 antibody research using humanized miceGruell, Henninga,b,c,d; Klein, Floriana,b,dAuthor Information aInstitute of Virology, University Hospital Cologne bLaboratory of Experimental Immunology, Center for Molecular Medicine Cologne (CMMC), University of Cologne cDepartment I of Internal Medicine, University Hospital Cologne dGerman Center for Infection Research, partner site Bonn-Cologne, Cologne, Germany Correspondence to Florian Klein, Laboratory of Experimental Immunology, Institute of Virology, University of Cologne, 50935 Cologne, Germany. Tel: +49 221 478 89693; e-mail: email@example.com Current Opinion in HIV and AIDS: May 2017 - Volume 12 - Issue 3 - p 285-293 doi: 10.1097/COH.0000000000000368 Buy Metrics Abstract Purpose of review Recent discoveries of highly potent broadly HIV-1 neutralizing antibodies provide new opportunities to successfully prevent, treat, and potentially cure HIV-1 infection. To test their activity in vivo, humanized mice have been shown to be a powerful model and were used to investigate antibody-mediated prevention and therapy approaches. In this review, we will summarize recent findings in humanized mice that have informed on the potential use of broadly neutralizing antibodies targeting HIV-1 in humans. Recent findings Humanized mouse models have been used to demonstrate the antiviral efficacy of HIV-1 neutralizing antibodies in vivo. It has been shown that a combination of antibodies can suppress viremia below the limit of detection and targets the HIV-1 reservoir. Moreover, passively administered antibodies and vector-mediated antibody production protect humanized mice from HIV-1 infection. Finally, immunization studies in knock-in/transgenic mice carrying human antibody gene segments have informed on potential vaccination strategies to induce broad and potent HIV-1 neutralizing antibodies. Summary Humanized mouse models are of great value for HIV-1 research. They represent a highly versatile in vivo system to investigate novel approaches for HIV-1 prevention and therapy and expedite the critical translation from basic findings to clinical application. Copyright © 2017 Wolters Kluwer Health, Inc. All rights reserved.